Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help

257 results

  1. pdfNewMeSHheadingsfor2021singlecolumnaftercutover.pdf 
    https://www.nlm.nih.gov/...adingsfor2021singlecolumnaftercutover.pdf
    ... is a functional receptor for the spike glycoprotein (SPIKE PROTEIN, CORONAVIRUS) of the CORONAVIRUSES SARS-COV, SARS-COV2, ... cell surface proteins that bind specifically to VIRAL SPIKE PROTEINS found on a CORONAVIRUS. The attachment of the ...
  2. Features, Evaluation, and Treatment of Coronavirus (COVID-19) - StatPearls - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK554776
    ... protein. N501Y shows an increased affinity of the spike protein to ACE 2 receptors, enhancing the viral attachment ... K417N, E484K, N501Y, D614G, and A701V) in the spike protein, of which 3 mutations (K417N, E484K, and N501Y) ...
  3. Imdevimab - StatPearls - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK572065
    ... drug. Imdevimab is a monoclonal antibody (mAb) against spike protein (S) of severe acute respiratory syndrome coronavirus 2 ( ... human immunoglobulin G1 (IgG1) monoclonal antibody to the spike protein of SARS-CoV-2. It binds to the ...
  4. Casirivimab - StatPearls - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK572124
    ... drug. Casirivimab is a monoclonal antibody (mAb) against spike protein (S) of severe acute respiratory syndrome coronavirus 2 ( ... human immunoglobulin G1 (IgG1) monoclonal antibody to the spike protein of SARS-CoV-2. It binds to the ...
  5. NLM Digital Collections - Technology assessment. Vaccine development : capabilities and challenges for addressing ... 
    Publication: Washington, DC : United States Government Accountability Office, November 2021
    resource.nlm.nih.gov/9918383084506676
    ... or the use of other cells, such as spike protein antigen was the result of decades of previous ... the SARS and Middle East Respiratory Syndrome (MERS) spike protein antigens and vaccines to address a diverse range ...
  6. NLM Digital Collections - Special assessment of outpatient treatments for COVID-19 : final evidence report and meeting .... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, May 10, 2022
    resource.nlm.nih.gov/9918506283506676
    ... could cause mutations in the SARS-CoV-2 spike protein, a key determinant of host antibody and targeted ... there is no clear evidence that emergence of spike protein amino acid changes in MOVe-OUT was associated ...
  7. NLM Digital Collections - Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use ... 
    Publication: Silver Spring, MD : Center for Drug Evaluation and Research, December 2023
    resource.nlm.nih.gov/9918751183806676
    ... receptor binding domain of the SARS-CoV-2 spike protein. Given this clinical context, FDA will continue to ... for a new mAb targeting SARS-CoV-2 spike protein should use the predominant circulating variant at that ...
  8. Bamlanivimab - StatPearls - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK576376
    ... is a monoclonal antibody (mAb) directed against the spike protein (S-Protein) of severe acute respiratory syndrome-coronavirus- ... a neutralizing immunoglobulin G1 variant mAb to the spike protein of SARS-CoV-2. It comprises 2 identical ...
  9. Etesevimab - StatPearls - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK572103
    ... antibody that targets the SARS-CoV-2 surface spike protein receptor-binding domain. Etesevimab is commonly labeled as ... nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 Jul; 17 (7):765- ...
  10. NLM Digital Collections - FDA oversight 
    Publication: [Toronto, Ontario] : Thomson Reuters, 19-December-2022
    resource.nlm.nih.gov/9918645959006676
    ... apart. The vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into ... the immune response of the vaccinated individual. The spike protein in this vaccine is produced in insect cells; ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last